Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study shows tezepelumab helps tame severe asthma

NCT ID NCT05677139

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the drug tezepelumab works for people with severe asthma when used in real-world settings, not just in controlled trials. Over 500 participants aged 12 and older were followed after starting tezepelumab. The main goal was to see if their asthma symptoms improved, using patient-reported questionnaires about breathing, nighttime waking, and activity limits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

513 people

The number who actually took part.

Started

Dec 2022

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants aged 12 years or older with severe uncontrolled asthma who will commence treatment with Tezepelumab and will be enrolled from a diverse population of clinical settings. In the first wave, the study population is planned to comprise approximately 200 participants with an additional 200 participants in the second wave.

Ages

12 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants aged 12 years or older * Provision of signed and dated written informed consent, including assent for minors * Prescribed treatment with Tezepelumab * Diagnosis of asthma for at least 52 weeks prior to enrolment date and symptoms confirmed by the Investigator not to be due to alternative diagnoses * Received at least one prescription of medium-dose to high-dose inhaled corticosteroids (ICS) during the 52 weeks prior to enrolment date * Use of additional asthma maintenance controller medication(s) for at least 52 weeks prior to enrolment date * Documented history of at least 1 asthma exacerbations during the 52 weeks prior to enrolment date * Individuals with ACQ-6 score ≥ 1.5 (indicating inadequate asthma symptom control) at enrolment or up to 12 weeks before enrolment * Participants currently receiving care from pulmonologists and/or allergists * Participants who are able to understand and complete the ePROs * Availability of participants medical records for asthma exacerbation and Healthcare Resource Utilization (HCRU) for the 52 weeks prior to Tezepelumab initiation Exclusion Criteria: * Any contraindication to Tezepelumab * Participants on concurrent biologics for asthma at the time of receiving the first dose of Tezepelumab will be excluded except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment) * Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months * Pregnancy or lactation period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Research Site

    Innsbruck, Austria

  • Research Site

    Klagenfurt, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Erpent, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Mouscron, Belgium

  • Research Site

    Woluwe-Saint-Lambert, Belgium

  • Research Site

    Yvoir, Belgium

  • Research Site

    Calgary, Alberta, T3B 0M3, Canada

  • Research Site

    Edmonton, Alberta, T6G 1C9, Canada

  • Research Site

    Vancouver, British Colombia, V6E 1Y6, Canada

  • Research Site

    Kingston, Ontario, K7M 7E4, Canada

  • Research Site

    Toronto, Ontario, M5G 1E2, Canada

  • Research Site

    Windsor, Ontario, N8X 5A6, Canada

  • Research Site

    Montreal, Quebec, H1T 2M4, Canada

  • Research Site

    Saskatoon, Saskatchewan, S7N 0W8, Canada

  • Research Site

    Copenhagen, Denmark

  • Research Site

    Hvidovre, Denmark

  • Research Site

    Vejle, Denmark

  • Research Site

    Aschaffenburg, Germany

  • Research Site

    Auerbach, Germany

  • Research Site

    Augsburg, Germany

  • Research Site

    Bamberg, Germany

  • Research Site

    Berlin, Germany

  • Research Site

    Bonn, Germany

  • Research Site

    Cottbus, Germany

  • Research Site

    Düsseldorf, Germany

  • Research Site

    Flensburg, Germany

  • Research Site

    Freiburg im Breisgau, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Hanover, Germany

  • Research Site

    Heidelberg, Germany

  • Research Site

    Leipzig, Germany

  • Research Site

    Marburg, Germany

  • Research Site

    München, Germany

  • Research Site

    Schleswig, Germany

  • Research Site

    Stuttgart, Germany

  • Research Site

    Völklingen, Germany

  • Research Site

    Wiesbaden, Germany

  • Research Site

    Jerusalem, Israel

  • Research Site

    Rehovot, Israel

  • Research Site

    Tel Aviv, Israel

  • Research Site

    Ancona, Italy

  • Research Site

    Bergamo, Italy

  • Research Site

    Catanzaro, Italy

  • Research Site

    Florence, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Palermo, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Siena, Italy

  • Research Site

    Tradate, Italy

  • Research Site

    Stockholm, Sweden

  • Research Site

    Uppsala, Sweden

  • Research Site

    Basel, Switzerland

  • Research Site

    Chur, Switzerland

  • Research Site

    Lugano, Switzerland

  • Research Site

    Sion, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.